Table 4.
Depicts E2, P4, and DHP concentrations in serum, midbrain, hippocampus, striatum, cortex, and interbrain of vehicle- (n=8) or E2-primed (n=8) rats that received no infusions and E2-primed rats that received 3α,5α-THP infusions to the VTA (n=9), SN (n=10), or CG (n=8)
| Experimental condition |
Serum | Midbrain | Hippocampus | Striatum | Cortex | Interbrain |
|---|---|---|---|---|---|---|
| E2 (ng/ml/g) | ||||||
| Vehicle control | 2.8±0.6 | 1.2±0.1 | 1.6±0.3 | 1.0±0.2 | 1.2±0.2 | 1.2±0.2 |
| E2 control | 27.8±3.8* | 2.6±0.3* | 3.2±0.5* | 2.1±0.2* | 1.5±0.1 | 3.7±0.4* |
| VTA 3α,5α-THP | 27.6±3.5* | 2.7±0.4* | 3.5±0.4* | 2.1±0.3* | 1.2±0.3 | 3.3±0.2* |
| SN 3α,5α-THP | 27.7±2.1* | 2.6±0.3* | 3.7±0.4* | 2.5±0.3* | 1.5±0.1 | 3.3±0.4* |
| CG 3α,5α-THP | 29.1±3.3* | 2.7±0.5* | 3.3±0.3* | 2.3±0.2* | 1.7±0.2 | 3.3±0.4* |
| P4 (ng/ml/g) | ||||||
| Vehicle control | 1.6±0.4 | 1.5±0.1 | 1.9±0.2 | 1.7±0.6 | 1.9±0.3 | 1.9±0.3 |
| E2 control | 1.3±0.4 | 1.6±0.1 | 1.8±0.2 | 1.6±0.1 | 1.9±0.2 | 1.9±0.2 |
| VTA 3α,5α-THP | 1.4±0.4 | 1.7±0.2 | 1.5±0.2 | 1.7±0.4 | 1.9±0.2 | 1.9±0.2 |
| SN 3α,5α-THP | 1.8±0.3 | 1.8±0.5 | 1.8±0.3 | 2.0±0.4 | 1.7±0.2 | 1.8±0.3 |
| CG 3α,5α-THP | 1.4±0.4 | 1.8±0.2 | 1.8±0.3 | 1.8±0.5 | 1.9±0.2 | 1.9±0.3 |
| DHP (ng/ml/g) | ||||||
| Vehicle control | 3.2±0.5 | 1.5±0.1 | 1.5±0.1 | 1.5±0.1 | 1.3±0.4 | 1.6±0.3 |
| E2 control | 3.4±0.5 | 1.7±0.1 | 1.8±0.3 | 1.7±0.1 | 2.1±0.6 | 1.4±0.3 |
| VTA 3α,5α-THP | 2.7±0.4 | 1.5±0.1 | 1.6±0.4 | 1.6±0.1 | 2.0±0.4 | 1.6±0.3 |
| SN 3α,5α-THP | 3.2±0.2 | 1.6±0.1 | 1.5±0.1 | 1.7±0.1 | 1.8±0.3 | 1.9±0.3 |
| CG 3α,5α-THP | 3.3±0.4 | 1.7±0.1 | 1.6±0.2 | 1.8±0.2 | 1.7±0.4 | 1.5±0.4 |
*
Indicates significant E2 enhancement in serum (F4,38=14.19, P<0.05), midbrain (F4,38=3.24, P<0.05), hippocampus F4,38=4.54, P<0.05), striatum [F4,38=4.52, P<0.05), and interbrain (F4,38=8.85, P<0.05).